2024 World Conference on Lung Cancer (WCLC) - Posters-P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA

P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA

Back to course

Pdf Summary

The European Program for Routine Testing of Patients with Advanced Lung Cancer (EPROPA) was introduced by Women Against Lung Cancer in Europe (WALCE) to tackle disparities in molecular testing and cancer care access across Europe. EPROPA provides free comprehensive genomic profiling specifically for non-small cell lung cancer (NSCLC) patients to identify actionable genetic mutations and increase their access to relevant clinical trials. The program engages 20 centers across countries like Albania, Greece, Italy, Romania, and Slovenia, focusing on molecular characterization to inform clinical trial eligibility. <br /><br />The study highlighted the feasibility and effectiveness of such initiatives in a real-world setting, demonstrating the potential to enhance molecular testing and trial enrollment, thereby reducing inequities in cancer treatment access across Europe. With 94% sample suitability, 555 cases were registered, and indeed, some were enrolled in clinical trials, despite some not being eligible or having trials available. <br /><br />The rapid turnaround time of 8 days for profiling results supports effective patient management. The main aim is to expand Next-Generation Sequencing (NGS)-based screening for metastatic NSCLC, promoting broader clinical trial participation for biomarker-driven treatments. Future plans include developing a spin-off program dedicated to the early stages of NSCLC to facilitate molecular characterizations in non-metastatic patients, further promoting both targeted therapies and immunotherapies.<br /><br />The paper implies the promising potential of genomic profiling in routine cancer care, advocating for continued efforts to establish similar programs and improve access to cutting-edge treatments and trials. The collective support of various regional hospitals and members highlights a multidimensional approach to advancing cancer care in Europe.

Asset Subtitle

Stefania Vallone

Meta Tag

Speaker Stefania Vallone

Topic Patient Advocacy

Keywords

EPROPA

WALCE

lung cancer

molecular testing

genomic profiling

NSCLC

clinical trials

Next-Generation Sequencing

cancer care

Europe